Our team are focused on improving the disease relevance of patient-derived models of early prostate cancer.
We have developed the Prostate Cancer dynamic screening platform (ProCASP) as a tool to study the effects of specific gene alterations. We are studying the genetic dependencies of early high risk disease models of prostate cancer, and whether functional insights can predict future outcomes. In addition, we can explore how altered expression of specific driver genes can impact upon the response to existing and emerging therapies. We are especially focused on the effects of DNA damaging agents, and identifying novel biomarkers of response and resistance, which we can further explore in clinical materials, through membership of the CRUK International Genome Consortium.
We have developed the Prostate Cancer dynamic screening platform (ProCASP) as a tool to study the effects of specific gene alterations. We are studying the genetic dependencies of early high risk disease models of prostate cancer, and whether functional insights can predict future outcomes. In addition, we can explore how altered expression of specific driver genes can impact upon the response to existing and emerging therapies. We are especially focused on the effects of DNA damaging agents, and identifying novel biomarkers of response and resistance, which we can further explore in clinical materials, through membership of the CRUK International Genome Consortium.
